ZV05
ZV05 (ZV0501 Antibody) is an anti-5T4 monoclonal antibody with an EC50 of 4.3 ng/mL against h5T4. ZV05 does not induce apoptosis or interfere with cell cycle progression. ZV05 accumulates specifically in 5T4-positive tumor xenografts. ZV05 can serve as the antibody component of antibody-active molecule conjugates (ADCs) to bind the 5T4 glycoprotein, thereby enabling targeted delivery of toxins. ZV05 is used in studies of 5T4-positive cancers, including triple-negative breast cancer.
For research use only. We do not sell to patients.
- Purity : ≥99.0%
- Molecular Weight:145.2 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
ZV05 (0.051-3000 ng/mL; 2 h) binds to the purified extracellular domain protein of h5T4, with an EC50 of 4.3 ng/mL[1].
ZV05 (0.01-10 μg/mL; 30 min on ice) specifically binds to the 5T4-positive cancer cell lines MDA-MB-468, DU 145 and BxPC-3, but does not bind to the 5T4-negative HepG2 or Ramos cell lines[1].
ZV05 (multiple concentrations; 72 h) shows no cytotoxicity against the 5T4-positive cancer cell lines MDA-MB-468, DU 145, BxPC-3, Lovo, as well as the 5T4-negative human cancer cell line HepG2 following 72 h of incubation[1].
ZV05 (0.139-10 μg/mL; 72 h) does not induce apoptosis in 5T4-positive MDA-MB-468 and DU 145 cancer cell lines even at concentrations up to 10 μg/mL after 72 h of incubation[1].
ZV05 (0.139-10 μg/mL; 72 h) does not interfere with cell cycle progression or induce G2/M phase arrest in the 5T4-positive human cancer cell lines MDA-MB-468 and DU 145, even at concentrations up to 10 μg/mL following a 72 h incubation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:5T4-positive human cancer cell lines (MDA-MB-468, DU 145, BxPC-3, Lovo); 5T4-negative HepG2 cell line
-
Concentration:Multiple concentrations
-
Incubation Time:72 h
-
Result:Showed no cytotoxicity on any tested 5T4-positive or 5T4-negative cell lines, with cell viability remaining near 100% across all concentrations.
-
Cell Line:5T4-positive human cancer cell lines (MDA-MB-468, DU 145)
-
Concentration:0.139-5 μg/mL (MDA-MB-468); 2.5-10 μg/mL (DU 145)
-
Incubation Time:72 h
-
Result:Resulted in a low percentage of apoptotic cells (nearly identical to the medium control) in a concentration-independent manner in both MDA-MB-468 and DU 145 cell lines.
-
Cell Line:5T4-positive human cancer cell lines (MDA-MB-468, DU 145)
-
Concentration:0.139-5 μg/mL (MDA-MB-468); 2.5-10 μg/mL (DU 145)
-
Incubation Time:72 h
-
Result:Resulted in cell cycle phase distributions that were concentration-independent and nearly identical to the medium control in both cell lines, with no G2/M phase arrest observed.
In Vivo
ZV05 (5 mg/kg; i.v.; single dose) does not specifically accumulate in 5T4-negative Romas tumor tissue in vivo[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude (female, 6-8 weeks old)[1]
-
Dosage:5 mg/kg
-
Administration:i.v.; single dose
-
Result:Accumulated rapidly in MDA-MB-468 tumor sites, reached a plateau, and remained detectable at 143 hours post-administration.
-
Animal Model:Balb/c nude (6-8 weeks old)[1]
-
Dosage:5 mg/kg
-
Administration:i.v.; single dose
-
Result:Distributed throughout internal organs and Romas tumor sites, with no specific tumor accumulation, consistent with Romas being a 5T4-negative cell line.
Gene ID
Accession
Target
TPBG
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human TPBG/5T4 Protein can bind ZV05. The ED50 for this effect is 53.6 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 145.2 kDa
-
Color Colorless to light yellow
-
Synonyms
ZV0501 Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)